会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • METHOD TO TRIGGER RNA INTERFERENCE
    • 触发RNA干扰的方法
    • US20110314571A1
    • 2011-12-22
    • US13216942
    • 2011-08-24
    • James C. CarringtonEdwards Allen
    • James C. CarringtonEdwards Allen
    • A01H5/00C12N5/10C12N15/82
    • C12N15/8279C12N15/111C12N15/113C12N15/8218C12N15/8245C12N15/8246C12N15/8247C12N15/8251C12N15/8261C12N15/8271C12N15/8274C12N15/8281C12N15/8283C12N15/8285C12N2310/14C12N2320/11
    • A method to generate siRNAs in vivo is described, as are constructs and compositions useful in the method. The method does not depend on the use of DNA or synthetic constructs that contain inverted duplications or dual promoters so as to form perfect or largely double-stranded RNA. Rather, the method depends on constructs that yield single-stranded RNA transcripts, and exploits endogenous or in vivo-produced miRNAs or siRNAs to initiate production of siRNAs. The miRNAs or siRNAs guide cleavage of the transcript and set the register for production of siRNAs (usually 21 nucleotides in length) encoded adjacent to the initiation cleavage site within the construct. The method results in specific formation of siRNAs of predictable size and register (phase) relative to the initiation cleavage site. The method can be used to produce specific siRNAs in vivo for inactivation or suppression of one or more target genes or other entities, such as pathogens.
    • 描述了在体内产生siRNA的方法,以及在该方法中有用的构建体和组合物。 该方法不依赖于使用含有反向重复或双重启动子的DNA或合成构建体,以形成完整或大部分双链RNA。 相反,该方法取决于产生单链RNA转录物的构建体,并利用内源或体内产生的miRNA或siRNA来引发siRNA的产生。 miRNA或siRNA指导转录物的切割,并设置用于生产与构建体内的起始切割位点相邻编码的siRNA(通常长度为21个核苷酸)的寄存器。 该方法导致相对于起始切割位点具有可预测大小和寄生(相)的siRNA的特异性形成。 该方法可用于在体内产生特异性siRNA以灭活或抑制一种或多种靶基因或其他实体,例如病原体。
    • 2. 发明授权
    • Method to trigger RNA interference
    • 触发RNA干扰的方法
    • US08030473B2
    • 2011-10-04
    • US11334776
    • 2006-01-06
    • James C. CarringtonEdwards Allen
    • James C. CarringtonEdwards Allen
    • C12N15/113C12N15/63C12N15/82
    • C12N15/8279C12N15/111C12N15/113C12N15/8218C12N15/8245C12N15/8246C12N15/8247C12N15/8251C12N15/8261C12N15/8271C12N15/8274C12N15/8281C12N15/8283C12N15/8285C12N2310/14C12N2320/11
    • A method to generate siRNAs in vivo is described, as are constructs and compositions useful in the method. The method does not depend on the use of DNA or synthetic constructs that contain inverted duplications or dual promoters so as to form perfect or largely double-stranded RNA. Rather, the method depends on constructs that yield single-stranded RNA transcripts, and exploits endogenous or in vivo-produced miRNAs or siRNAs to initiate production of siRNAs. The miRNAs or siRNAs guide cleavage of the transcript and set the register for production of siRNAs (usually 21 nucleotides in length) encoded adjacent to the initiation cleavage site within the construct. The method results in specific formation of siRNAs of predictable size and register (phase) relative to the initiation cleavage site. The method can be used to produce specific siRNAs in vivo for inactivation or suppression of one or more target genes or other entities, such as pathogens.
    • 描述了在体内产生siRNA的方法,以及在该方法中有用的构建体和组合物。 该方法不依赖于使用含有反向重复或双重启动子的DNA或合成构建体,以形成完整或大部分双链RNA。 相反,该方法取决于产生单链RNA转录物的构建体,并利用内源或体内产生的miRNA或siRNA来引发siRNA的产生。 miRNA或siRNA指导转录物的切割,并设置用于生产与构建体内的起始切割位点相邻编码的siRNA(通常长度为21个核苷酸)的寄存器。 该方法导致相对于起始切割位点具有可预测大小和寄生(相)的siRNA的特异性形成。 该方法可用于在体内产生特异性siRNA以灭活或抑制一种或多种靶基因或其他实体,例如病原体。
    • 6. 发明授权
    • Method and vector for the purification of foreign proteins
    • 用于纯化外源蛋白的方法和载体
    • US5179007A
    • 1993-01-12
    • US377438
    • 1989-07-07
    • Donald L. JarvisJames C. Carrington
    • Donald L. JarvisJames C. Carrington
    • C07K14/01C07K14/08C12N9/50C12N15/62C12N15/866
    • C12N15/86C07K14/005C12N15/62C12N9/503C07K2319/09C07K2319/50C07K2319/61C12N2710/14143C12N2770/34022
    • The present invention provides an method for isolating and purifying recombinantly produced proteins. This invention involves the use of an expression vector which includes a nuclear targeting signal sequence which effectively directs newly synthesized proteins to the nucleus; a cleavage recognition sequence which cleaves specifically at a pre-determined cleavage site after addition of a viral enzyme; and a cDNA sequence which codes for a desired protein. Specifically the production and isolation of a desired protein is accomplished through the use of lepidopteran cells transfected or infected with recombinant baculovirus expression vector comprising a polyhedrin gene derived nuclear targeting signal sequence and a cleavage recognition sequence derived from a potyvirus polyprotein. The newly synthesized proteins are directed into the nucleus whereupon nuclear protein is extracted from the nucleus. Thereafter the desired protein is bound to an affinity matrix embedded with antibodies directed against the nuclear targeting sequence. Afterwards the desired protein is cleaved from the affinity matrix with the addition of a viral enzyme.
    • 本发明提供了分离和纯化重组产生的蛋白质的方法。 本发明涉及使用表达载体,其包括有效地将新合成的蛋白质引导至细胞核的靶向靶向信号序列; 在添加病毒酶之后在预定切割位点特异性切割的切割识别序列; 和编码所需蛋白质的cDNA序列。 具体地,通过使用转染或感染重组杆状病毒表达载体的鳞翅目细胞来实现所需蛋白质的生产和分离,所述重组杆状病毒表达载体包含衍生自多核苷酸基因的靶向信号序列和衍生自病毒多蛋白的切割识别序列。 新合成的蛋白质被导入细胞核,从核中提取核蛋白质。 此后,所需的蛋白质与嵌入针对核靶向序列的抗体的亲和基质结合。 之后,通过加入病毒酶将所需蛋白质从亲和基质上切下。